Literature DB >> 7353129

Trimethoprim resistance in Finland after five years' use of plain trimethoprim.

P Huovinen, P Toivanen.   

Abstract

A total of 1388 urinary bacterial pathogens were tested for resistance to plain trimethoprim after five years' use of this drug for prophylaxis against urinary tract infections. Samples were obtained in Turku, Finland, where use of the drug is much greater than in other parts of Finland. Resistance to trimethoprim (greater than 8 mg/l; agar-dilution method) occurred in 20.3% of strains isolated from outpatients and 39.8% of strains isolated from inpatients. Escherichia coli and Micrococcus showed low incidences of resistance (11% and 13% respectively in ouptatients and 23% and 19% respectively in inpatients); Enterobacter, Streptococcus faecalis, and Staphylococcus epidermidis occupied an intermediate position; and Proteus mirabilis and Klebsiella were resistant in 41-76% of cases. Similar incidences of resistance were observed to sulphamethoxazole-trimethoprim, sulphamethoxazole, ampicillin, and nitrofurantoin. These findings together with the rare occurrence of side effects and convenient dosage confirm the usefulness of plain trimethoprim for urinary tract infection.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7353129      PMCID: PMC1600228          DOI: 10.1136/bmj.280.6207.72

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  13 in total

1.  Trimethoprim R factors in enterobacteria from clinical specimens.

Authors:  R S Jobanputra; N Datta
Journal:  J Med Microbiol       Date:  1974-05       Impact factor: 2.472

2.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

3.  Trimethoprim-resistant coliforms.

Authors:  R W Lacey; D M Bruten; W A Gillespie; E L Lewis
Journal:  Lancet       Date:  1972-02-19       Impact factor: 79.321

4.  Trimethoprim-resistant coliforms.

Authors:  P J Marks; D M Bruten; D C Speller
Journal:  Lancet       Date:  1977-10-08       Impact factor: 79.321

5.  Trimethoprim-resistant Klebsiella aerogenes.

Authors:  R E McGill
Journal:  Lancet       Date:  1978-07-15       Impact factor: 79.321

6.  Trimethoprim--resistant coliforms.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

7.  Alterations in the sensitivity pattern after use of trimethoprim-sulfamethoxazole for two years in the treatment of urinary tract infections.

Authors:  K Fruensgaard; B Korner
Journal:  Chemotherapy       Date:  1974       Impact factor: 2.544

8.  Effect of trimethoprim on the occurrence of drug-resistant coliform bacteria in the faecal flora.

Authors:  A Toivanen; A Kasan; H Sundquist; P Toivanen
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

9.  [Trimethoprim resistance plasmids: transferability and incompatibility groups (author's transl)].

Authors:  J F Acar; F W Goldstein; G R Gerbaud; Y A Chabbert
Journal:  Ann Microbiol (Paris)       Date:  1977-01

10.  Trimethoprim resistance determined by R factors.

Authors:  M P Fleming; N Datta; R N Grüneberg
Journal:  Br Med J       Date:  1972-03-18
View more
  15 in total

1.  Five-year survey of changing patterns of susceptibility of bacterial uropathogens to trimethoprim-sulfamethoxazole and other antimicrobial agents.

Authors:  U Alon; G Davidai; M Berant; D Merzbach
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

Review 2.  Trimethoprim and sulfonamide resistance.

Authors:  P Huovinen; L Sundström; G Swedberg; O Sköld
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

3.  Another look at trimethoprim-sulfamethoxazole: its role in parenteral therapy.

Authors:  F R Sattler; J S Remington
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

Review 4.  Fixed combination drug therapy.

Authors:  G M Shenfield
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

5.  Resistance of urine pathogens to trimethoprim in Finland.

Authors:  S Räisänen; N Keränen; H Syrjälä
Journal:  J Clin Pathol       Date:  1982-01       Impact factor: 3.411

6.  Resistance to trimethoprim in 1978-79 compared with 1973-75.

Authors:  J M Hamilton-Miller; A Gooding; W Brumfitt
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

Review 7.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

8.  Characterization of trimethoprim resistance by use of probes specific for transposon Tn7.

Authors:  L Pulkkinen; P Huovinen; E Vuorio; P Toivanen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Trimethoprim and co-trimoxazole in the treatment of acute urinary tract infections: patient compliance and efficacy.

Authors:  D A Andrewes; P J Chuter; M J Dawson; B W Eden; R M Moore; D S Freestone; C A Morris
Journal:  J R Coll Gen Pract       Date:  1981-05

10.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.